Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

U.S. revokes approval of Avastin for breast cancer

WASHINGTON (Reuters) - U.S. drug regulators on Friday withdrew approval of Roche's Avastin as a treatment for breast cancer, capping a protracted and emotional battle over a drug backed by many survivors of the disease.

Doctors split on Avastin for breast cancer: survey

NEW YORK (Reuters Health) - An international survey of cancer doctors shows many question U.S. health advisers' 2010 rejection of Roche's drug Avastin to treat advanced breast cancer.

Calif. insurer won't pay for breast cancer drug

(Reuters) - Health insurer Blue Shield of California has decided not to pay for Roche Holding's drug Avastin to treat breast cancer after health advisers said it was not safe or clinically beneficial.

Novartis's Afinitor shows promise in breast cancer

STOCKHOLM (Reuters) - Combining two drugs from Novartis and Pfizer to treat post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, study data showed on Monday.

Roche's pertuzumab helps breast cancer patients

ZURICH (Reuters) - Patients with advanced breast cancer lived significantly longer without their disease getting worse when treated with Roche's pertuzumab and Herceptin along with a type of chemotherapy, a late-stage study showed.

Novartis gets good news on cancer drug Afinitor

ZURICH (Reuters) - Novartis AG said a late-stage study showed its drug hope Afinitor slowed tumor growth in advanced breast cancer, helping its chances of becoming a new blockbuster treatment.

Medicare will keep covering Roche's Avastin

WASHINGTON (Reuters) - Medicare will continue coverage of Roche Holdings' drug Avastin for breast cancer regardless of what U.S. health regulators decide about the medicine, a spokesperson for the U.S. health insurer said.

Roche undeterred after FDA's Avastin rebuff

ZURICH (Reuters) - Swiss drugmaker Roche Holding AG had nothing to lose by giving Avastin another roll of the dice, and by doing so showed the world it still believes the drug should be used in breast cancer.

US FDA panel rejects Avastin for breast cancer use

SILVER SPRING, Md. (Reuters) - U.S. health advisers delivered a blow to Roche Holding on Wednesday, voting to reject the use of Roche Holding drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.

FDA Invites Comments on Avastin

FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.